Scholar Rock (NASDAQ:SRRK) shares surged by greater than 30% Monday in response to the failed Section 3 trial of a competitor’s SMA drug.
Truist analysts lifted the corporate’s value goal to $45.00 from the earlier $36.00, whereas sustaining a Purchase score on the inventory. This revision follows a latest growth the place a competing pharmaceutical firm encountered a setback within the Spinal Muscular Atrophy (SMA) market.
Based on the analyst from Truist Securities, the failed Section 3 trial of a competitor’s SMA drug has bolstered the case for Scholar Rock’s candidate, Apitegromab, which has proven statistically important enhancements within the situation. Because of these developments, the agency has raised its peak gross sales estimate for Apitegromab to $1.5 billion, up from $1.2 billion.
The analyst’s revised value goal of $45.00 per share displays a extra optimistic valuation, knowledgeable by the assumption that the SMA market alternative could also be bigger than beforehand anticipated.
This reassessment is partly because of the diminished aggressive strain following the competitor’s trial miss. The report additionally notes that every extra $100 million in anticipated peak gross sales may probably add one other $3.00 per share to Scholar Rock’s discounted money movement (DCF) valuation.
Moreover, Scholar Rock’s Apitegromab just isn’t solely making progress in SMA, however it’s also at present in a Section 2 trial for weight problems, with information anticipated within the second quarter of 2024. The Truist analyst identified that this weight problems trial just isn’t but factored into their monetary mannequin.
In gentle of those components, the analyst believes that Scholar Rock presents itself as a beautiful acquisition goal, given its constructive SMA information and the continuing growth of Apitegromab for extra indications.
This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.
